Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Breast Neoplasms 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 57Biopsy 44pembrolizumab 38Carboplatin 32Nivolumab 29Cyclophosphamide 27Radiotherapy 26Radiation 25Paclitaxel 24Cisplatin 24olaparib 21Etoposide 19Doxorubicin 18durvalumab 17Taxes 17Radiotherapy, Intensity-Modulated 17Dexamethasone 17Bevacizumab 17X-Rays 16Vincristine 16Prednisone 16Immunoglobulin G 16Disulfides 16Cytarabine 15Platinum 14Leucovorin 14Docetaxel 14Pemetrexed 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × patritumab deruxtecan × 30 days × Clear all
NCT04699630 2026-05-22

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

SCRI Development Innovations, LLC

Phase 2 Completed
121 enrolled 15 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡